Researchers Testing Stem Cells To Treat Alzheimer’s
April 14, 2016
By Alexandria Hein
In a first-of-its-kind clinical trial, researchers at the University of Miami Miller School of Medicine are using mesenchymal stem cells (MSCs) in an attempt to slow or reverse the symptoms of Alzheimer’s disease. The team is aiming to enroll 30 patients who will be tested and observed for cognitive function, memory, quality of life and brain volume over the course of a year.
“This is a phase 1 study; we want to prove that it’s safe,” Dr. Bernard Baumel, principal investigator and an assistant professor of neurology at the Miller School of Medicine, told FoxNews.com. “We minimally would like to see that it slows down the progression of the disease.”
Baumel and his team began investigating MSCs because of their anti-inflammatory properties and because they have shown the ability to develop into many different types of cells. The cells are also thought to promote neurogenesis, which allows the brain to produce new cells in the hippocampus, which is where new memory forms and Alzheimer’s disease begins.
“[MSCs] are anti-inflammatory and they promote indigenous stem cells in your body to proliferate,” Baumel said. “They stimulate cell growth and have a lot of attributes that are very advantageous for using them in humans.”
One such attribute is the ability to migrate to areas in the body in which they are needed. Baumel explained that if you were to inject stem cells into the body of someone who had no need for them, they would simply wither away and die. However, for the patients enrolled in the trial, due to the pathology of Alzheimer’s Baumel and his team hope to see the MSCs cross the blood brain barrier and help reduce inflammation, stimulate neural stem cells to proliferate and repair damaged areas. In a best case scenario, Baumel said the team would see MSCs remove the brain inflammation associated with Alzheimer’s altogether.
The approach has previously been tested in mice with promising results. Researchers pathologically altered the mouse to replicate Alzheimer’s disease, which saw an increase in amyloid plaque build-up and caused them to struggle to move through a maze. Mice treated with MSCs had a marked reduction in plaque and showed improved behavior.
“It’s the first time it is being done [in humans],” Baumel said. “There’s been no successful study done therapeutically since 2002, so we’re very excited that this is a new approach to Alzheimer’s therapy, and hopefully it will work.”
There currently is no cure for Alzheimer’s, a progressive disease that is the most common form of dementia. More than 5 million Americans suffer from Alzheimer’s, with symptoms including memory loss, confusion, disorientation and mood and behavior changes.
The Allogeneic Human Mesenchymal Stem Cell Infusion Versus Placebo in Patients with Alzheimer’s Disease study is being conducted in collaboration with Joshua M. Hare, M.D., founding director of the Interdisciplinary Stem Cell Institute at the University of Miami Miller School of Medicine and Louis Lemberg, professor of medicine.
Longeveron is researching treatments based on its Mesenchymal Stem Cells for a variety of aging-related diseases. In 2017, Longeveron published positive Phase I and Phase 2 clinical studies in the Journals of Gerontology that evaluated the safety and efficacy of its Mesenchymal Stem Cells in patients with Aging Frailty, a serious geriatric syndrome that can lead to other severe health conditions, such as heart disease. The company is now recruiting for an expanded Phase 2b Aging Frailty study.
Longeveron is also recruiting for a Phase 1 Alzheimer’s trial, and Phase 1 and 2 trials to evaluate the safety and efficacy of its stem cells for improving flu vaccine immune response in Aging Frailty patients. Longeveron’s MSC product is derived from the bone marrow of young, healthy adult donors.
Longeveron () is a regenerative medicine therapy company founded in 2014. Longeveron’s goal is to provide the first of its kind biological solution for aging-related diseases, and is dedicated to developing safe cell-based therapeutics to revolutionize the aging process and improve quality of life. The company’s research focus areas Aging Frailty, the Metabolic Syndrome and Alzheimer’s Disease and gratefully acknowledges the generous support of the National Institutes of Health, the Alzheimer’s Association and Maryland Stem Cell Research Fund. Longeveron is also conducting a Phase 1 trial to study Hypoplastic Left Heart Syndrome, a rare indication that affects infants, supported through a grant from the Maryland Stem Cell Research Fund.
For more information about the clinical trials
Longeveron is sponsoring, visit ClinicalTrials.gov
or Longeveron’s website www.longeveron.com
SOURCE Longeveron LLC